Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Sartorius Stedim Biotech Extends Portfolio with Majority Stake in AllPure Technologies

By BiotechDaily International staff writers
Posted on 04 May 2014
Sartorius Stedim Biotech (SSB; Aubagne, France) has signed a contract to acquire the majority stake in the privately owned start-up AllPure Technologies LLC (New Oxford, PA, USA). AllPure Technologies designs, manufactures, and markets innovative aseptic sampling and tube sealing systems for biopharmaceutical and pharmaceutical drug developers and manufacturers; it has been on the market for 4 years, and in 2013 earned revenue of around USD 3 million, with 25 employees. SSB, dedicated to a philosophy of “turning science into solutions,” is a leading global R&D company and provider of cutting-edge equipment, products, and services for the pharmaceutical and biotech industries; it employs approx. 3,300 people, and in 2013 earned sales revenue of EUR 588.4 million.

The takeover extends SSB's portfolio for single-use bioprocessing as AllPure specializes in innovative single-use components for biopharmaceutical applications, such as aseptic sampling techniques. AllPure has launched advanced products to improve operating efficiencies, process reliability, and operator safety. Supported by numerous patent-pending technologies, its products provide quick, reliable, and safe solutions to the shortcomings of current aseptic sampling techniques. AllPure operates in a state-of-the-art facility, and complies with applicable cGMP guidelines.

“AllPure further completes our portfolio with innovative products that help our customers develop and manufacture their pharmaceutical drugs safer and more efficiently. I am really looking forward to working with the AllPure team and to all that we can accomplish together,” said Reinhard Vogt, member of SSB’s Executive Board. "We are excited to leverage Sartorius Stedim’s impressive R&D capabilities so that we can accelerate the launch of new products from AllPure. And SSB’s global reach and industry relationships grant access to considerably more customers, especially in Europe and Asia, which have tremendous potential for AllPure’s products,” said Michael Zumbrum, President of AllPure. SSB and AllPure agreed not to disclose further details of the purchase agreement.

Related Links:

Sartorius Stedim Biotech 
AllPure Technologies 



Channels

Genomics/Proteomics

view channel
Image: The bone marrow of mice with normal ether lipid production (top) contains more white blood cells than are found in the bone marrow of mice with ether lipid deficiency (bottom) (Photo courtesy of Washington University School of Medicine).

Inactivating Fatty Acid Synthase Reduces Inflammation by Interfering with Neutrophil Membrane Function

The enzyme fatty acid synthase (FAS) was shown to regulate inflammation by sustaining neutrophil viability through modulation of membrane phospholipid composition. Neutrophils are the most abundant... Read more

Drug Discovery

view channel
Image: Researchers have attached two drugs—TRAIL and Dox—onto graphene strips. TRAIL is most effective when delivered to the external membrane of a cancer cell, while Dox is most effective when delivered to the nucleus, so the researchers designed the system to deliver the drugs sequentially, with each drug hitting a cancer cell where it will do the most damage (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Therapeutics

view channel
Image: Cancer cells infected with tumor-targeted oncolytic virus (red). Green indicates alpha-tubulin, a cell skeleton protein. Blue is DNA in the cancer cell nuclei (Photo courtesy of Dr. Rathi Gangeswaran, Bart’s Cancer Institute).

Innovative “Viro-Immunotherapy” Designed to Kill Breast Cancer Cells

A leading scientist has devised a new treatment that employs viruses to kill breast cancer cells. The research could lead to a promising “viro-immunotherapy” for patients with triple-negative breast cancer,... Read more

Lab Technologies

view channel
Image: MIT researchers have designed a microfluidic device that allows them to precisely trap pairs of cells (one red, one green) and observe how they interact over time (Photo courtesy of Burak Dura, MIT).

New Device Designed to See Communication between Immune Cells

The immune system is a complicated network of many different cells working together to defend against invaders. Effectively combating an infection depends on the interactions between these cells.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.